Replies to post #18788 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

These are my predictions for next week’s CC:

• A generally upbeat tone—as though GTC’s cash register were going ka-ching and there were ample reasons for shareholders to be happy.

• Plenty of hot air about what a fantastic job GTC is doing to build shareholder value via its myriad preclinical programs and partnerships. The recent FoB partnership deals will be highly touted, but there will be no mention of the fact that these deals are bringing no new money into GTC’s coffers (and may even be causing a small money outflow).

• No change in the status of the ongoing “talks” about finding a new partner to assume Leo’s obligations for the development and marketing of ATryn in Europe, Canada, and the Middle East. (Corollary: there will be no plan for a resumption of the phase-2 ATryn trial in DIC/sepsis.)

• No progress on inking a Japanese partnership for ATryn.

• No discussion whatsoever about what it will mean for shareholders if the LFB loan is not repaid by June 1 and GTC opts to assume control of GTC’s BoD (as LFB is contractually entitled to do upon conversion of their note and warrants).

Regards, Dew

p.s. MTB, your latest post sounds like something vinmantoo might have written, and that’s not a good thing.

[fraseriv]

MTB, until now each time COX speaks, the stock suffers a heart attack. So why is this time going to be different???

[vinmantoo]

MTB,

GTCB's cc have been disappointing in the past so I won't hold my breath waiting for good news. If there is going to be some news, I am hoping it will be related to European ATRYN rights, with Lundbeck/Ovation being the most likely candidate given their rapid movement of ATRYN onto the market in the US.

[biopearl]

http://finance.yahoo.com/news/GTC-Biotherapeutics-Regains-bw-15219414.html?.v=1 I'm sure Dr. Cox and Co will be crowing about this tidbit. (Market cap 35 million--how much have they spent so far--about 10x that amount) bp